

# An RNA toolbox for cancer immunotherapy

Nature Reviews Drug Discovery

17, 751-767

DOI: [10.1038/nrd.2018.132](https://doi.org/10.1038/nrd.2018.132)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Aptamer-iRNAs as Therapeutics for Cancer Treatment. <i>Pharmaceuticals</i> , 2018, 11, 108.	1.7	37
2	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. <i>Molecular Therapy</i> , 2019, 27, 1878-1891.	3.7	38
3	LncRNAs as Chromatin Regulators in Cancer: From Molecular Function to Clinical Potential. <i>Cancers</i> , 2019, 11, 1524.	1.7	59
4	Cellular RNA surveillance in health and disease. <i>Science</i> , 2019, 366, 822-827.	6.0	95
5	Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. <i>Nature Communications</i> , 2019, 10, 3974.	5.8	302
6	Multicistronic IVT mRNA for simultaneous expression of multiple fluorescent proteins. <i>Journal of Industrial and Engineering Chemistry</i> , 2019, 80, 770-777.	2.9	5
7	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN- $\beta$ . <i>Journal of Immunology</i> , 2019, 203, 696-704.	0.4	6
8	Messenger RNA delivery by hydrazone-activated polymers. <i>MedChemComm</i> , 2019, 10, 1138-1144.	3.5	11
9	RNA delivery biomaterials for the treatment of genetic and rare diseases. <i>Biomaterials</i> , 2019, 217, 119291.	5.7	50
10	RNA Aptamers Targeting Integrin $\alpha 5 \beta 1$ as Probes for Cyto- and Histofluorescence in Glioblastoma. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 63-77.	2.3	26
11	mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo. <i>Molecular Therapy</i> , 2019, 27, 1415-1423.	3.7	125
12	Theranostic Nanoparticles for RNA-Based Cancer Treatment. <i>Accounts of Chemical Research</i> , 2019, 52, 1496-1506.	7.6	111
13	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. <i>Chemical Society Reviews</i> , 2019, 48, 3771-3810.	18.7	292
14	A New Era for Rare Genetic Diseases: Messenger RNA Therapy. <i>Human Gene Therapy</i> , 2019, 30, 1180-1189.	1.4	54
15	Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides. <i>Molecular Pharmaceutics</i> , 2019, 16, 2265-2277.	2.3	69
16	Therapeutic mRNA delivery to leukocytes. <i>Journal of Controlled Release</i> , 2019, 305, 165-175.	4.8	43
17	Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1924.	1.8	126
18	mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. <i>Molecular Therapy</i> , 2019, 27, 757-772.	3.7	297

#	ARTICLE	IF	CITATIONS
19	Precision immunomodulation with synthetic nucleic acid technologies. <i>Nature Reviews Materials</i> , 2019, 4, 451-458.	23.3	27
20	Messenger RNA therapy for rare genetic metabolic diseases. <i>Gut</i> , 2019, 68, 1323-1330.	6.1	76
21	Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer. <i>Pharmaceutics</i> , 2019, 11, 684.	2.0	12
22	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. <i>Cancer Cell</i> , 2019, 36, 613-629.e7.	7.7	99
23	Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 46585-46590.	4.0	63
24	Targeting mRNA processing as an anticancer strategy. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 112-129.	21.5	131
25	Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1582.	3.3	32
26	Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 581-601.	2.3	74
27	Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. <i>Vaccines</i> , 2020, 8, 360.	2.1	12
28	Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 587997.	1.6	274
29	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. <i>OncImmunology</i> , 2020, 9, 1796002.	2.1	63
30	Lipid-Nucleic Acid Complexes: Physicochemical Aspects and Prospects for Cancer Treatment. <i>Molecules</i> , 2020, 25, 5006.	1.7	31
31	Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy. <i>Frontiers in Chemistry</i> , 2020, 8, 589959.	1.8	157
32	Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. <i>Langmuir</i> , 2020, 36, 13331-13341.	1.6	28
33	Engineering Prodrug Nanomedicine for Cancer Immunotherapy. <i>Advanced Science</i> , 2020, 7, 2002365.	5.6	71
34	The Expression Profile of mRNA and tRNA Genes in Splenocytes and Neutrophils after In Vivo Delivery of Antitumor Short Hairpin RNA of Indoleamine 2,3-Dioxygenase. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6703.	1.8	0
35	Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts. <i>Cancers</i> , 2020, 12, 1365.	1.7	8
36	Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11368-11396.	2.9	128

#	ARTICLE	IF	CITATIONS
37	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. <i>Pharmaceutics</i> , 2020, 12, 520.	2.0	16
38	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1455-1489.	1.5	22
39	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1771143.	2.1	116
40	Promising RNA-based cancer gene therapy using extracellular vesicles for drug delivery. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 767-777.	1.4	19
41	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 147.	2.2	39
42	Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 801-809.	0.9	19
43	Rapid Delivery of Nanobodies/VHHs into Living Cells via Expressing In Vitro-Transcribed mRNA. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 401-408.	1.8	18
44	Targeting Plk1 with siRNAs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients. <i>Scientific Reports</i> , 2020, 10, 2688.	1.6	11
45	Enhancing cancer immunotherapy with nanomedicine. <i>Nature Reviews Immunology</i> , 2020, 20, 321-334.	10.6	506
46	Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2793.	1.8	89
47	The potential underlying mechanism of the leukemia caused by MLL fusion and potential treatments. <i>Molecular Carcinogenesis</i> , 2020, 59, 839-851.	1.3	6
48	Delivery of nucleic acid therapeutics for cancer immunotherapy. <i>Medicine in Drug Discovery</i> , 2020, 6, 100023.	2.3	22
49	Structural Insights into the Interaction of Clinically Relevant Phosphorothioate mRNA Cap Analogs with Translation Initiation Factor 4E Reveal Stabilization via Electrostatic Thio-Effect. <i>ACS Chemical Biology</i> , 2021, 16, 334-343.	1.6	16
50	Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	0.7	9
51	Vaccination as Immunotherapy in Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 433-443.	0.8	8
52	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. <i>Frontiers in Immunology</i> , 2020, 11, 620283.	2.2	2
53	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 615240.	2.2	59
54	Oligonucleotide-Based Therapies for Renal Diseases. <i>Biomedicines</i> , 2021, 9, 303.	1.4	10

#	ARTICLE	IF	CITATIONS
55	RNA-based therapies: A cog in the wheel of lung cancer defense. <i>Molecular Cancer</i> , 2021, 20, 54.	7.9	53
56	Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. <i>ACS Central Science</i> , 2021, 7, 748-756.	5.3	196
57	mRNA therapeutics in cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 69.	7.9	168
58	Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 692982.	1.8	12
59	Stoichiometry of multi-specific immune checkpoint RNA Abs for T <sup>A</sup> cell activation and tumor inhibition using ultra-stable RNA nanoparticles. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 426-435.	2.3	5
60	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
61	Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA. <i>Cell Chemical Biology</i> , 2022, 29, 312-320.e7.	2.5	14
62	Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 682129.	1.3	2
63	Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids. <i>Pharmaceuticals</i> , 2021, 14, 841.	1.7	7
64	Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 92-106.	5.7	66
65	Aptamers: Cutting edge of cancer therapies. <i>Molecular Therapy</i> , 2021, 29, 2396-2411.	3.7	52
66	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. <i>Acta Biomaterialia</i> , 2021, 131, 16-40.	4.1	140
67	Advances in mRNA-based drug discovery in cancer immunotherapy. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 41-53.	2.5	17
68	Aptamer-mediated transcriptional gene silencing of Foxp3 inhibits regulatory T <sup>A</sup> cells and potentiates antitumor response. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 25, 143-151.	2.3	4
69	Polysaccharide-based nanomedicines for cancer immunotherapy: A review. <i>Bioactive Materials</i> , 2021, 6, 3358-3382.	8.6	74
70	High-Throughput Automation of Endosomolytic Polymers for mRNA Delivery. <i>ACS Applied Bio Materials</i> , 2021, 4, 1640-1654.	2.3	15
71	Fluorescent aptamers for detection and treatment of pathogenic bacteria and cancer. <i>Methods in Microbiology</i> , 2021, 48, 135-177.	0.4	0
72	Cancer vaccines: translational strategies. , 2021, , 307-328.		0

#	ARTICLE	IF	CITATIONS
73	Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination. <i>Methods in Molecular Biology</i> , 2021, 2197, 13-31.	0.4	33
74	Cancer Genomics in Precision Oncology: Applications, Challenges, and Prospects. , 2020, , 453-499.		9
75	RNA to the rescue. <i>EMBO Reports</i> , 2020, 21, e51013.	2.0	8
76	Cancer Nanoimmunotherapy: Recent Advances and New Opportunities. <i>Nanotechnology in the Life Sciences</i> , 2021, , 155-173.	0.4	0
77	RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer. <i>Pharmaceutics</i> , 2021, 13, 1694.	2.0	17
78	Influence of the media ionic strength on the formation and in vitro biological performance of polycation-DNA complexes. <i>Journal of Molecular Liquids</i> , 2021, 344, 117930.	2.3	2
79	Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11790.	1.8	13
80	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	3.2	0
81	Cancer immunomodulation using bispecific aptamers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 894-915.	2.3	20
82	The tiny big world of solid lipid nanoparticles and nanostructured lipid carriers: an updated review. <i>Journal of Microencapsulation</i> , 2022, 39, 72-94.	1.2	18
83	Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders. <i>Biomedicines</i> , 2022, 10, 158.	1.4	11
84	Neoantigens and their potential applications in tumor immunotherapy (Review). <i>Oncology Letters</i> , 2022, 23, 88.	0.8	10
86	Nucleic acid-based vaccines. , 2022, , 227-245.		0
87	The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA. <i>Pharmaceutics</i> , 2022, 14, 460.	2.0	11
88	RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. <i>Molecular Cancer</i> , 2022, 21, 58.	7.9	33
89	Native RNA Purification Method for Small RNA Molecules Based on Asymmetrical Flow Field-Flow Fractionation. <i>Pharmaceutics</i> , 2022, 15, 261.	1.7	6
90	Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	156
91	3D Melanoma Cocultures as Improved Models for Nanoparticle-Mediated Delivery of RNA to Tumors. <i>Cells</i> , 2022, 11, 1026.	1.8	4

#	ARTICLE	IF	CITATIONS
92	Rapid Surface Display of mRNA Antigens by Bacteria-Derived Outer Membrane Vesicles for a Personalized Tumor Vaccine. <i>Advanced Materials</i> , 2022, 34, e2109984.	11.1	82
93	mRNA cancer vaccines: Advances, trends and challenges. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2969-2989.	5.7	55
95	Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 345, 586-600.	4.8	12
96	Albumin-binding lipid-aptamer conjugates for cancer immunoimaging and immunotherapy. <i>Science China Chemistry</i> , 2022, 65, 574-583.	4.2	12
97	Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2410, 649-670.	0.4	11
98	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	3.2	6
99	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
100	The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114316.	6.6	17
101	Current Advances in Aptamer-based Biomolecular Recognition and Biological Process Regulation. <i>Chemical Research in Chinese Universities</i> , 2022, 38, 847-855.	1.3	6
103	Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment. <i>International Review of Cell and Molecular Biology</i> , 2022, , 65-122.	1.6	4
104	Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 405-425.	1.5	3
105	Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatfrom with immune escape and homologous targeting for colon cancer therapy. <i>Materials Today Bio</i> , 2022, 15, 100294.	2.6	6
106	RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System. <i>Clinical Cancer Research</i> , 2022, 28, 3929-3939.	3.2	7
107	Overcoming the limitations of cytokines to improve cancer therapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 107-141.	1.6	7
108	Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	19
109	Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy. <i>Frontiers in Nanotechnology</i> , 0, 4, .	2.4	3
110	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
111	Nanoparticle entry into cells; the cell biology weak link. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114403.	6.6	31

#	ARTICLE	IF	CITATIONS
112	Tools shaping drug discovery and development. <i>Biophysics Reviews</i> , 2022, 3, .	1.0	3
113	Aptamers as Theragnostic Tools in Prostate Cancer. <i>Biomolecules</i> , 2022, 12, 1056.	1.8	8
114	Application of lipid-based nanoparticles in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
115	Application of mRNA Technology in Cancer Therapeutics. <i>Vaccines</i> , 2022, 10, 1262.	2.1	7
116	Unprotonatable and ROS-sensitive Nanocarrier for NIR Spatially Activated siRNA Therapy with Synergistic Drug Effect. <i>Small</i> , 2022, 18, .	5.2	12
117	Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. <i>Theranostics</i> , 2022, 12, 6422-6436.	4.6	36
118	Lipid nanomaterials-based RNA therapy and cancer treatment. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 903-915.	5.7	14
119	An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
120	Exploring the potential of eRNAs in cancer immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 197-199.	2.0	0
121	RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug. <i>Oncolmunology</i> , 2022, 11, .	2.1	0
122	Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics. <i>Bioactive Materials</i> , 2023, 23, 438-470.	8.6	13
124	Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. <i>Acta Biomaterialia</i> , 2023, 158, 698-707.	4.1	3
125	Immunomodulation with Nucleic Acid Nanodevices. <i>Small</i> , 2023, 19, .	5.2	4
127	Aptamer-based rapid diagnosis for point-of-care application. <i>Microfluidics and Nanofluidics</i> , 2023, 27, .	1.0	15
128	Nanomaterials for mRNA-based therapeutics: Challenges and opportunities. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	14
129	Recent progress of aptamer-drug conjugates in cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1358-1370.	5.7	18
130	Enzymatic Synthesis of Base-Modified Nucleic Acids. , 2023, , 1-39.		0
131	STAT3 silencing by an aptamer-based strategy hampers the crosstalk between NSCLC cells and cancer-associated fibroblasts. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 32, 111-126.	2.3	2



#	ARTICLE	IF	CITATIONS
132	Chemistry, structure and function of approved oligonucleotide therapeutics. <i>Nucleic Acids Research</i> , 2023, 51, 2529-2573.	6.5	110
133	The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6121.	1.8	2
134	In silico antibody-peptide epitope prediction for personalized cancer therapy. <i>Frontiers in Applied Mathematics and Statistics</i> , 0, 9, .	0.7	0
135	Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166720.	1.8	6
136	mRNA vaccination in breast cancer: current progress and future direction. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 9435-9450.	1.2	3
137	<i>In Vitro</i> Evolution and Aptamers. , 2022, , 403-420.		0
148	Immunotherapy for Meningiomas. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 225-234.	0.8	0
164	Advances in liposome-based delivery of RNA therapeutics for cancer treatment. <i>Progress in Molecular Biology and Translational Science</i> , 2024, , 177-218.	0.9	0
165	Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact. <i>Npj Vaccines</i> , 2024, 9, .	2.9	0
167	RNA therapeutics for diarrhea. <i>Progress in Molecular Biology and Translational Science</i> , 2024, , 295-309.	0.9	0